









Registered Address: Chemicea Pharmaceuticals Pvt Ltd, Platinum Springs,

Unit No- A- 205&206 Second floor, Plot No: G-6, G-20 to G 24, Taloja- MIDC, Opp. Dena Bank

Navi Mumbai 410208, MH, INDIA. Email- info@chemicea.com Mob- +91 9284897978

CERTIFICATE OF ANALYSIS

Analysis Date: Nov 2022 Re-test Date: Oct 2025

Product Name: Apixaban Impurity 9

Identification:

 $Chemical\ Name:\ Ethyl\ 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo \cite{A-pyrazolo} and the pyrazolo \ci$

c]pyridine-3-carboxylate

Synonyms : Apixaban Ethyl Ester Impurity

CAS Number : 503614-91-3

CAT Number : CP-A3006

Molecular Formula : C27H28N4O5

Molecular Weight : 488.54

Batch Number : CHEM-ETH-EST

Storage Condition : Tightly closed, Inert atmosphere at 2 to 8° C

Shipping condition : All Products are stable to be shipped at room temperature, if specific condition required it is

mention in the COA

Analytical Information:

| Sr. No. | Test | Result |
|---------|--------------------|--------------------------|
| 1) | Description | White Solid |
| 2) | Solubility | Soluble in Methanol/DMSO |
| 3) | MASS By LCMS | Confirm to structure |
| 4) | Purity By HPLC | 99.58% |
| 5) | H1NMR | Confirm to structure |
| 6) | 13CNMR | Confirm to structure |
| 7) | Weight loss by TGA | 0.31% |
| 8) | Potency by TGA | 99.27% |



Prepared and Reviewed By

Sign of the same

Ms Priyanka Salunkhe (Manager QC Analytical) **Approved By**



Ms Rohini Gagare (QA Head)

| Note: Product supplied by Chemicea are for R&D purpose only and not for human consumptions. | | | | |
|---|--|--|--|--|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |